Polyrizon Ltd. Appoints Dr. Michal Meir to Lead Regulatory Affairs
Ticker: PLRZ · Form: 6-K · Filed: Dec 19, 2024 · CIK: 1893645
| Field | Detail |
|---|---|
| Company | Polyrizon Ltd. (PLRZ) |
| Form Type | 6-K |
| Filed Date | Dec 19, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: personnel, regulatory-affairs, pharmaceuticals
TL;DR
Polyrizon beefs up regulatory team with Dr. Michal Meir appointment.
AI Summary
Polyrizon Ltd. announced on December 19, 2024, the appointment of Dr. Michal Meir as its new Senior Director of Regulatory and Clinical Affairs. Dr. Meir brings extensive experience to the role, which is crucial for the company's development and market entry of its pharmaceutical preparations.
Why It Matters
This appointment is significant as it strengthens Polyrizon's leadership team in a critical area for pharmaceutical companies, potentially accelerating product development and regulatory approvals.
Risk Assessment
Risk Level: low — The filing is a routine announcement of a personnel appointment and does not contain significant financial or operational risks.
Key Players & Entities
- Polyrizon Ltd. (company) — The company making the announcement.
- Dr. Michal Meir (person) — Newly appointed Senior Director of Regulatory and Clinical Affairs.
- December 19, 2024 (date) — Date of the press release and filing.
FAQ
What is Polyrizon Ltd.'s primary business sector?
Polyrizon Ltd. is in the Pharmaceutical Preparations sector, SIC code 2834.
When was this Form 6-K filed?
This Form 6-K was filed on December 19, 2024.
Who is the new Senior Director of Regulatory and Clinical Affairs at Polyrizon?
Dr. Michal Meir has been appointed as the new Senior Director of Regulatory and Clinical Affairs.
What is the address of Polyrizon Ltd.'s principal executive offices?
The address is 5 Ha-Tidhar Street Raanana, 4366507, Israel.
What type of annual report does Polyrizon Ltd. file?
Polyrizon Ltd. files its annual reports under cover of Form 20-F.
Filing Stats: 188 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2024-12-19 08:21:38
Filing Documents
- ea0225323-6k_polyrizon.htm (6-K) — 10KB
- ea022532302ex99-1_polyrizon.htm (EX-99.1) — 9KB
- 0001213900-24-110312.txt ( ) — 19KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Polyrizon Ltd. Date: December 19, 2024 By: /s/ Tomer Izraeli Name: Tomer Izraeli Title: Chief Executive Officer 2